Cross-Border Talk: Know When to Fold ’Em — Rethinking Steroids & Eczema Care (Part 2) kapak görseli

Cross-Border Talk: Know When to Fold ’Em — Rethinking Steroids & Eczema Care (Part 2)

Cross-Border Talk: Know When to Fold ’Em — Rethinking Steroids & Eczema Care (Part 2)

Şimdi ücretsiz dinle, üyelik gerekmez

Program ayrıntılarını görüntüle

This Season's Biggest Deal | £0.99/mo for 3 months + £10 Audible bonus

£5.99/mo after 3 months - terms apply. Cancel monthly
🇨🇦🇺🇸 Cross-Border Talk: High Fives, Higher Standards — Rethinking the Treatment Finish Line (Part 2 of 2)🎰 What happens in Vegas doesn't always stay in Vegas—especially when it could change how we treat patients! 🇨🇦 Team Canada and 🇺🇸 Team USA are back for Round 2!Live from Fall Clinical 2026 in Las Vegas, Canadian dermatologist Dr. Andrei Metelitsa and American dermatologist Dr. Christopher Bunick return to the Skin and Joints Podcast for Part 2 of our Cross-Border Talk series.This time we're raising the stakes—and the standard of care.🤔 What good is a better eczema score if your patient still can't sleep, work, or even shake someone's hand?Our experts go beyond skin clearance to explore why minimal disease activity, patient-reported outcomes, and real-world functionality should be central to how we define treatment success in atopic dermatitis and chronic hand eczema.🔬 Diving deeper into the AD Hand study, they unpack emerging tralokinumab data showing meaningful improvements in quality of life and hand function. But how quickly should patients expect results? And when is an improving partial response good enough—or a signal to rethink the treatment plan?🩺 Then comes the ultimate cross-border real world clinical challenge: a 38 year old nurse whose painful hand eczema threatens her ability to work, despite optimized topical therapy. Would Team Canada and Team USA approach treatment differently? When is it time to escalate therapy—and what happens once patients finally achieve clear skin?💡 From biologics and JAK inhibitors to shared decision-making, irritant avoidance, and the intriguing question of what happens after patients achieve clear skin, this conversation serves up practical clinical pearls—with a few laughs along the way.🙌 Two countries. One treatment goal. Helping patients high-five with confidence again! 🎯 Learning ObjectivesFollowing this episode, healthcare professionals should be able to:Redefine meaningful treatment success: Discuss the clinical value of minimal disease activity and more stringent treat-to-target goals, integrating skin clearance, itch control, and patient-reported outcomes rather than relying solely on conventional disease severity scores.Translate clinical trial findings into real-world outcomes: Interpret findings from the AD Hand study examining tralokinumab's impact on Dermatology Life Quality Index (DLQI) and Hand Eczema Impact Scale (HEIS) outcomes, and consider their relevance to daily functioning and quality of life.Set realistic treatment expectations: Evaluate the significance of early responses, continued improvement over time, and partial treatment responses when counselling patients with atopic hand eczema, while recognizing the importance of ongoing skin care and irritant avoidance.Navigate treatment escalation in high-burden disease: Apply a patient-centred approach to clinical decision-making in patients with functionally debilitating atopic hand eczema, including consideration of biologics, JAK inhibitors, occupational factors, concomitant therapies, and differences in treatment availability across Canada and the United States.Look beyond achieving clear skin: Explore emerging considerations for long-term disease control, maintenance strategies, dosing flexibility, and potential treatment de-escalation once patients achieve meaningful disease control, while recognizing the limits of current evidence. 🎲 The stakes are high, the clinical pearls are plenty, and the borders are open for debate.Because at the end of the day, successful eczema treatment isn't just about how the skin looks—it's about what patients can finally get back to doing. 🙌#SkinAndJoints #CrossBorderTalk #FallClinical2026 #AtopicDermatitis #ChronicHandEczema #ADHand #JAKs #MinimalDiseaseActivity #PatientReportedOutcomes #Dermatology #TreatToTarget SUPPORTED BY AN IME GRANT FROM LEO Pharma. About Dr. Christopher Bunick MD, PhD.Dermatologist | New Haven, CT, USA BIOGRAPHYDr. Christopher Bunick is an Associate Professor of Dermatology and Translational Biomedicine at Yale University School of Medicine. Clinically, he specializes in general medical dermatology and dermatologic surgery. He also performs unique dermatologic research studying the three-dimensional structures of skin-related proteins using x-ray crystallography and cryo-electron microscopy. Dr. Bunick received his B.S. at Vanderbilt University (Nashville, TN), and his M.D. and Ph.D. degrees at Vanderbilt University School of Medicine. His PhD research studied the three-dimensional structures of calcium-binding proteins and proteins involved in DNA repair processes (e.g. the skin disease xeroderma pigmentosum). He completed medical internship, dermatology residency, and a dermatology research fellowship (mentored by Nobel Laureate Dr. Thomas A. Steitz) at the Yale University School of Medicine (New Haven, CT). He performs lab research with the goal ...
adbl_web_anon_alc_button_suppression_t1
Henüz yorum yok